Matches in SemOpenAlex for { <https://semopenalex.org/work/W2810651102> ?p ?o ?g. }
Showing items 1 to 87 of
87
with 100 items per page.
- W2810651102 abstract "Introduction In recent years, immunotherapy including checkpoint blockade acts as potential strategies to cure cancer. A number of recent studies have identified inducible co-stimulator (ICOS) as a crucial player in the immune checkpoints blockade therapy. ICOS, a homodimeric protein which belongs to CD28 superfamily, is expressed on activated T cells and resting memory T cells. Upon inflammation, ICOS and its ligand ICOSL (B7RP-1, B7H-2) have been shown to affect T cell responses via ICOS-mediated PI3-kinase signalling to enhance the T cells development and activity. In addition, previous studies have shown that upon CTLA-4 blockade, the ICOS/ICOSL pathway plays an important role in tumour immunity. In this study, we aim to develop and implement the Fc-fusion recombinant ICOSL proteins to induce T cells activation for therapeutic use. Our data suggested that recombinant ICOSL-Fc can enhance the proliferation and cytotoxicity effect of human Pan T cells by increasing INFg and IL10 secretion. Moreover, ICOSL-Fc can also inhibit tumour growth in xenograft animal models. Based on our study, ICOS/ICOSL pathway could be a promising therapeutic target for the immunotherapy. Material and methods Expression and Purification of Recombinant ICOSL Proteins Construction of Fc-fusion ICOSL proteins: ICOS-mFc, mICOS-mFc, and ICOSL-Fc Expression and purification of recombinant ICOSL proteins Employ Flow Cytometry and ELISA-Based Assay to Confirm ICOSL-Fc Fusion Protein Can Bind to ICOS Perform ICOS binding ELISA assay with fusion ICOSL-Fc protein. Perform Pan T cell flow binding assay with fusion ICOSL-Fc protein. Results and discussions ICOSL-Fc can induce secretion of INFγ and IL-10, and proliferation of human Pan T cells. The tumour specific ICOSL-Fc engagement increases the cytotoxicity of human PBMC Conclusion Expressions of PD1, ICOS and CTLA4 can be observed in PBMC under CD3/CD28 stimulation on day 1, day 3, and day 5. Recombinant human ICOSL-Fc protein was able to bind to both human ICOS and mouse ICOS ECD domains. Cell-base immunofluorescence was employed to illustrate recombinant human ICOSL-Fc protein was able to bind activated T cells. 3H-Thymidine incorporation study illustrated that recombinant ICOSL-Fc was able to increase T cells proliferation. In vitro efficacy assay suggested that recombinant ICOSL-Fc can remarkable increase IL-10 and INFγ secretion on human pan T cells. The preliminary T cell cytotoxicity assay showed ICOSL-Fc treatment can increase the killing effect." @default.
- W2810651102 created "2018-07-10" @default.
- W2810651102 creator A5007729715 @default.
- W2810651102 creator A5030404799 @default.
- W2810651102 creator A5032381041 @default.
- W2810651102 creator A5075971265 @default.
- W2810651102 creator A5078038915 @default.
- W2810651102 creator A5080107071 @default.
- W2810651102 date "2018-06-01" @default.
- W2810651102 modified "2023-09-27" @default.
- W2810651102 title "PO-095 ICOS: a crucial immunomodulator for development of immunotherapy" @default.
- W2810651102 doi "https://doi.org/10.1136/esmoopen-2018-eacr25.622" @default.
- W2810651102 hasPublicationYear "2018" @default.
- W2810651102 type Work @default.
- W2810651102 sameAs 2810651102 @default.
- W2810651102 citedByCount "0" @default.
- W2810651102 crossrefType "journal-article" @default.
- W2810651102 hasAuthorship W2810651102A5007729715 @default.
- W2810651102 hasAuthorship W2810651102A5030404799 @default.
- W2810651102 hasAuthorship W2810651102A5032381041 @default.
- W2810651102 hasAuthorship W2810651102A5075971265 @default.
- W2810651102 hasAuthorship W2810651102A5078038915 @default.
- W2810651102 hasAuthorship W2810651102A5080107071 @default.
- W2810651102 hasBestOaLocation W28106511021 @default.
- W2810651102 hasConcept C104317684 @default.
- W2810651102 hasConcept C123894998 @default.
- W2810651102 hasConcept C148125776 @default.
- W2810651102 hasConcept C170493617 @default.
- W2810651102 hasConcept C185592680 @default.
- W2810651102 hasConcept C203014093 @default.
- W2810651102 hasConcept C2776090121 @default.
- W2810651102 hasConcept C2777701055 @default.
- W2810651102 hasConcept C2778468042 @default.
- W2810651102 hasConcept C2780405999 @default.
- W2810651102 hasConcept C2780674031 @default.
- W2810651102 hasConcept C40767141 @default.
- W2810651102 hasConcept C502942594 @default.
- W2810651102 hasConcept C553184892 @default.
- W2810651102 hasConcept C55493867 @default.
- W2810651102 hasConcept C86803240 @default.
- W2810651102 hasConcept C8891405 @default.
- W2810651102 hasConcept C95444343 @default.
- W2810651102 hasConceptScore W2810651102C104317684 @default.
- W2810651102 hasConceptScore W2810651102C123894998 @default.
- W2810651102 hasConceptScore W2810651102C148125776 @default.
- W2810651102 hasConceptScore W2810651102C170493617 @default.
- W2810651102 hasConceptScore W2810651102C185592680 @default.
- W2810651102 hasConceptScore W2810651102C203014093 @default.
- W2810651102 hasConceptScore W2810651102C2776090121 @default.
- W2810651102 hasConceptScore W2810651102C2777701055 @default.
- W2810651102 hasConceptScore W2810651102C2778468042 @default.
- W2810651102 hasConceptScore W2810651102C2780405999 @default.
- W2810651102 hasConceptScore W2810651102C2780674031 @default.
- W2810651102 hasConceptScore W2810651102C40767141 @default.
- W2810651102 hasConceptScore W2810651102C502942594 @default.
- W2810651102 hasConceptScore W2810651102C553184892 @default.
- W2810651102 hasConceptScore W2810651102C55493867 @default.
- W2810651102 hasConceptScore W2810651102C86803240 @default.
- W2810651102 hasConceptScore W2810651102C8891405 @default.
- W2810651102 hasConceptScore W2810651102C95444343 @default.
- W2810651102 hasLocation W28106511021 @default.
- W2810651102 hasOpenAccess W2810651102 @default.
- W2810651102 hasPrimaryLocation W28106511021 @default.
- W2810651102 hasRelatedWork W1484140899 @default.
- W2810651102 hasRelatedWork W1535248058 @default.
- W2810651102 hasRelatedWork W1913256683 @default.
- W2810651102 hasRelatedWork W1976983285 @default.
- W2810651102 hasRelatedWork W1991180497 @default.
- W2810651102 hasRelatedWork W2112135890 @default.
- W2810651102 hasRelatedWork W2174267452 @default.
- W2810651102 hasRelatedWork W2345544817 @default.
- W2810651102 hasRelatedWork W2355896134 @default.
- W2810651102 hasRelatedWork W2378501241 @default.
- W2810651102 hasRelatedWork W2401368754 @default.
- W2810651102 hasRelatedWork W2487544631 @default.
- W2810651102 hasRelatedWork W2504565138 @default.
- W2810651102 hasRelatedWork W2782963254 @default.
- W2810651102 hasRelatedWork W2895864000 @default.
- W2810651102 hasRelatedWork W2903049725 @default.
- W2810651102 hasRelatedWork W3030622803 @default.
- W2810651102 hasRelatedWork W3033907435 @default.
- W2810651102 hasRelatedWork W3157157309 @default.
- W2810651102 hasRelatedWork W2625806972 @default.
- W2810651102 isParatext "false" @default.
- W2810651102 isRetracted "false" @default.
- W2810651102 magId "2810651102" @default.
- W2810651102 workType "article" @default.